Monica L Guzman

List of Publications by Year in Descending Order

125 papers	5,001 citations	32 h-index	70 g-index
128 ext. papers	6,035 ext. citations	7.4 avg, IF	5.18 L-index

#	Paper	IF	Citations
125	Mutant - and -Driven Hematopoiesis Populates the Hematopoietic Compartment in Response to Peptide Receptor Radionuclide Therapy.. *JCO Precision Oncology*, **2022**, 6, e2100309	3.6	0
124	Methods to monitor in vivo expansion and efficacy of CAR-T cells in preclinical models.. *Methods in Cell Biology*, **2022**, 167, 185-201	1.8	
123	Technical Aspects of Flow Cytometry-based Measurable Residual Disease Quantification in Acute Myeloid Leukemia: Experience of the European LeukemiaNet MRD Working Party.. *HemaSphere*, **2022**, 6, e676	0.3	3
122	Allogeneic TCR deficient CAR T-cells targeting CD123 in acute myeloid leukemia.. *Nature Communications*, **2022**, 13, 2227	17.4	2
121	Targeting CD123 in blastic plasmacytoid dendritic cell neoplasm using allogeneic anti-CD123 CAR T cells.. *Nature Communications*, **2022**, 13, 2228	17.4	0
120	Patient-Derived Bone Marrow Spheroids Reveal Leukemia-Initiating Cells Supported by Mesenchymal Hypoxic Niches in Pediatric B-ALL. *Frontiers in Immunology*, **2021**, 12, 746492	8.4	3
119	DNMT3A and TET2 mutant Clonal Hematopoiesis May Drive a Proinflammatory State and Predict Enhanced Response to Immune Checkpoint Inhibitors. *Blood*, **2021**, 138, 4295-4295	2.2	0
118	The Prognostic Value of Early Measurable Residual Disease Assessment in Patients with Acute Myeloid Leukemia Treated with Intensive Chemotherapy - Preliminary Results of Polish Adult Leukemia Group PALG-AML1/2016 Study. *Blood*, **2021**, 138, 3453-3453	2.2	
117	The CBF SMMHC/NRP1 Axis Regulates FLT3 and TGF-Beta Pathways in Inv(16) Acute Myeloid Leukemia. *Blood*, **2021**, 138, 3314-3314	2.2	
116	2021 Update Measurable Residual Disease in Acute Myeloid Leukemia: European LeukemiaNet Working Party Consensus Document. *Blood*, **2021**,	2.2	33
115	Inhibiting autophagy targets human leukemic stem cells and hypoxic AML blasts by disrupting mitochondrial homeostasis. *Blood Advances*, **2021**, 5, 2087-2100	7.8	8
114	Mutant PPM1D and TP53 populate the hematopoietic compartment after peptide receptor radionuclide therapy (PRRT) exposure.. *Journal of Clinical Oncology*, **2021**, 39, 10605-10605	2.2	
113	Targeting the epichaperome as an effective precision medicine approach in a novel PML-SYK fusion acute myeloid leukemia. *Npj Precision Oncology*, **2021**, 5, 44	9.8	6
112	Small-molecule inhibitors targeting Polycomb repressive complex 1 RING domain. *Nature Chemical Biology*, **2021**, 17, 784-793	11.7	7
111	Macrophages in Acute Myeloid Leukaemia: Significant Players in Therapy Resistance and Patient Outcomes. *Frontiers in Cell and Developmental Biology*, **2021**, 9, 692800	5.7	3
110	BCL6 maintains survival and self-renewal of primary human acute myeloid leukemia cells. *Blood*, **2021**, 137, 812-825	2.2	3
109	Comparison of Multiple Clinical Testing Modalities for Assessment of NPM1-Mutant AML. *Frontiers in Oncology*, **2021**, 11, 701318	5.3	1

108	CD123 as a Therapeutic Target Against Malignant Stem Cells. *Hematology/Oncology Clinics of North America*, **2020**, 34, 553-564	3.1	10
107	Applicability and reproducibility of acute myeloid leukaemia stem cell assessment in a multi-centre setting. *British Journal of Haematology*, **2020**, 190, 891-900	4.5	5
106	Clonal Hematopoiesis in Patients with Neuroendocrine Tumors Receiving Peptide Receptor Radionuclide Therapy (PRRT). *Blood*, **2020**, 136, 35-36	2.2	
105	Clonal Hematopoiesis in Patients Receiving Immune Checkpoint Inhibitor Therapy. *Blood*, **2020**, 136, 15-16	2.2	
104	Menin inhibitor MI-3454 induces remission in MLL1-rearranged and NPM1-mutated models of leukemia. *Journal of Clinical Investigation*, **2020**, 130, 981-997	15.9	72
103	Chaperome Networks Redundancy and Implications for Cancer Treatment. *Advances in Experimental Medicine and Biology*, **2020**, 1243, 87-99	3.6	5
102	Chemical probes and methods for single-cell detection and quantification of epichaperomes in hematologic malignancies. *Methods in Enzymology*, **2020**, 639, 289-311	1.7	5
101	Clonal Hematopoiesis and Premalignant Diseases. *Cold Spring Harbor Perspectives in Medicine*, **2020**, 10,	5.4	5
100	The therapeutic landscape for cells engineered with chimeric antigen receptors. *Nature Biotechnology*, **2020**, 38, 233-244	44.5	75
99	Clonal Hematopoiesis Before, During, and After Human Spaceflight. *Cell Reports*, **2020**, 33, 108458	10.6	6
98	A Chemical Biology Approach to the Chaperome in Cancer-HSP90 and Beyond. *Cold Spring Harbor Perspectives in Biology*, **2020**, 12,	10.2	22
97	Telomere Trimming and DNA Damage as Signatures of High Risk Neuroblastoma. *Neoplasia*, **2019**, 21, 689-701	6.4	6
96	Rational Targeting of Cooperating Layers of the Epigenome Yields Enhanced Therapeutic Efficacy against AML. *Cancer Discovery*, **2019**, 9, 872-889	24.4	22
95	FDA-approved ferumoxytol displays anti-leukaemia efficacy against cells with low ferroportin levels. *Nature Nanotechnology*, **2019**, 14, 616-622	28.7	127
94	Paradigms for Precision Medicine in Epichaperome Cancer Therapy. *Cancer Cell*, **2019**, 36, 559-573.e7	24.3	25
93	PTPN11 Mutated Acute Myeloid Leukemia (AML) Features an Abundant Epichaperome Network and Is Sensitive to the Epichaperome Inhibitor PU-H71. *Blood*, **2019**, 134, 3935-3935	2.2	
92	Antecedent Clonal Hematopoesis and Risk of and Mortality after Solid and Hematological Malignancies: Analyses from the Women Health Initiative Study. *Blood*, **2019**, 134, 1199-1199	2.2	0
91	Epichaperome Abundance Predicts Response to the Epichaperome Inhibitor, Puh-71, in Acute Myeloid Leukemia. *Blood*, **2019**, 134, 5145-5145	2.2	

90	Efficacy Proof of Concept for Allogeneic CD123 Targeting CAR T-Cells Against Primary Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Efficient Control of Tumor Progression in PDX Model and Potential Loss of CD123 Expression in Relapsed Disease. *Blood*, **2019**, 134, 2659-2659	2.2	
89	Harnessing the Epichaperome As a Therapeutic Approach in Multiple Myeloma. *Blood*, **2019**, 134, 4399-4399	2.2	
88	Cranberry A-type proanthocyanidins selectively target acute myeloid leukemia cells. *Blood Advances*, **2019**, 3, 3261-3265	7.8	2
87	Approaches to Targeting Cancer Stem Cells in Solid Tumors. *Current Stem Cell Research and Therapy* , **2019**, 14, 421-427	3.6	3
86	Chaperome heterogeneity and its implications for cancer study and treatment. *Journal of Biological Chemistry*, **2019**, 294, 2162-2179	5.4	27
85	A novel tetrazole analogue of resveratrol is a potent anticancer agent. *Bioorganic and Medicinal Chemistry Letters*, **2019**, 29, 172-178	2.9	22
84	CD25 expression and outcomes in older patients with acute myelogenous leukemia treated with plerixafor and decitabine. *Leukemia and Lymphoma*, **2018**, 59, 821-828	1.9	8
83	Parthenolide and DMAPT induce cell death in primitive CML cells through reactive oxygen species. *Journal of Cellular and Molecular Medicine*, **2018**, 22, 4899-4912	5.6	8
82	Oncogenic hijacking of the stress response machinery in T cell acute lymphoblastic leukemia. *Nature Medicine*, **2018**, 24, 1157-1166	50.5	51
81	Somatic mutations precede acute myeloid leukemia years before diagnosis. *Nature Medicine*, **2018**, 24, 1015-1023	50.5	265
80	Potential for subsets of wt-NPM1 primary AML blasts to respond to retinoic acid treatment. *Oncotarget*, **2018**, 9, 4134-4149	3.3	9
79	Synthesis and Evaluation of 2-Naphthaleno trans-Stilbenes and Cyanostilbenes as Anticancer Agents. *Anti-Cancer Agents in Medicinal Chemistry*, **2018**, 18, 556-564	2.2	6
78	Selection and characterization of antibody clones are critical for accurate flow cytometry-based monitoring of CD123 in acute myeloid leukemia. *Leukemia and Lymphoma*, **2018**, 59, 978-982	1.9	8
77	Minimal Residual Disease in Acute Myeloid Leukemia. *Advances in Experimental Medicine and Biology*, **2018**, 1100, 111-125	3.6	7
76	Epigenetic Identity in AML Depends on Disruption of Nonpromoter Regulatory Elements and Is Affected by Antagonistic Effects of Mutations in Epigenetic Modifiers. *Cancer Discovery*, **2017**, 7, 868-883	24.4	69
75	GLI3 repressor determines Hedgehog pathway activation and is required for response to SMO antagonist glasdegib in AML. *Blood*, **2017**, 129, 3465-3475	2.2	38
74	Minimal Residual Disease Monitoring of Acute Myeloid Leukemia by Massively Multiplex Digital PCR in Patients with NPM1 Mutations. *Journal of Molecular Diagnostics*, **2017**, 19, 537-548	5.1	48
73	Single-cell RNA sequencing reveals a signature of sexual commitment in malaria parasites. *Nature*, **2017**, 551, 95-99	50.4	121

72	Prostaglandin E1 and Its Analog Misoprostol Inhibit Human CML Stem Cell Self-Renewal via EP4 Receptor Activation and Repression of AP-1. *Cell Stem Cell*, **2017**, 21, 359-373.e5	18	32
71	Novel strategies for targeting leukemia stem cells: sounding the death knell for blood cancer. *Cellular Oncology (Dordrecht)*, **2017**, 40, 1-20	7.2	20
70	Distinct evolution and dynamics of epigenetic and genetic heterogeneity in acute myeloid leukemia. *Nature Medicine*, **2016**, 22, 792-9	50.5	217
69	Small Molecule Inhibitor of CBFβ-RUNX Binding for RUNX Transcription Factor Driven Cancers. *EBioMedicine*, **2016**, 8, 117-131	8.8	57
68	Pro-inflammatory-Related Loss of CXCL12 Niche Promotes Acute Lymphoblastic Leukemic Progression at the Expense of Normal Lymphopoiesis. *Frontiers in Immunology*, **2016**, 7, 666	8.4	22
67	Pre-Clinical Studies of Anti-CD123 CAR-T Cells for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). *Blood*, **2016**, 128, 4039-4039	2.2	15
66	Allogeneic TcrαβDeficient CAR T-Cells Targeting CD123 Prolong Overall Survival of AML Patient-Derived Xenografts. *Blood*, **2016**, 128, 765-765	2.2	13
65	MSI2 is required for maintaining activated myelodysplastic syndrome stem cells. *Nature Communications*, **2016**, 7, 10739	17.4	18
64	Dehydroleucodine, a Sesquiterpene Lactone from Gynoxys verrucosa, Demonstrates Cytotoxic Activity against Human Leukemia Cells. *Journal of Natural Products*, **2016**, 79, 691-6	4.9	12
63	Evolution of acute myelogenous leukemia stem cell properties after treatment and progression. *Blood*, **2016**, 128, 1671-8	2.2	127
62	The epichaperome is an integrated chaperome network that facilitates tumour survival. *Nature*, **2016**, 538, 397-401	50.4	148
61	Single-cell mass cytometry reveals intracellular survival/proliferative signaling in FLT3-ITD-mutated AML stem/progenitor cells. *Cytometry Part A: the Journal of the International Society for Analytical Cytology*, **2015**, 87, 346-56	4.6	65
60	Pharmacologic inhibition of the Menin-MLL interaction blocks progression of MLL leukemia in vivo. *Cancer Cell*, **2015**, 27, 589-602	24.3	212
59	A Hyperactive Signalosome in Acute Myeloid Leukemia Drives Addiction to a Tumor-Specific Hsp90 Species. *Cell Reports*, **2015**, 13, 2159-73	10.6	41
58	CDK6 is a regulator of stem cells "Egr" to wake up. *Blood*, **2015**, 125, 7-9	2.2	3
57	Synthesis, anticancer activity and molecular docking studies on a series of heterocyclic trans-cyanocombretastatin analogues as antitubulin agents. *European Journal of Medicinal Chemistry*, **2015**, 92, 212-20	6.8	15
56	Chemical biology. A small-molecule inhibitor of the aberrant transcription factor CBFβ-SMMHC delays leukemia in mice. *Science*, **2015**, 347, 779-84	33.3	80
55	Synthesis and evaluation of a series of resveratrol analogues as potent anti-cancer agents that target tubulin. *MedChemComm*, **2015**, 6, 788-794	5	26

54	TCRab Deficient CAR T-Cells Targeting CD123: An Allogeneic Approach of Adoptive Immunotherapy for the Treatment of Acute Myeloid Leukemia (AML). *Blood*, **2015**, 126, 2555-2555	2.2	2
53	Divergent Dynamics of Epigenetic and Genetic Heterogeneity in Relapsed Acute Myeloid Leukemia. *Blood*, **2015**, 126, 306-306	2.2	2
52	A Role for IL1RAP in Acute Myelogenous Leukemia Stem Cells Following Treatment and Progression. *Blood*, **2015**, 126, 4266-4266	2.2	1
51	A Hyperactive Signalosome Results in High Sensitivity to HSP90 Inhibitors in AML. *Blood*, **2015**, 126, 2567-2567	2.2	
50	Concise review: Leukemia stem cells in personalized medicine. *Stem Cells*, **2014**, 32, 844-51	5.8	40
49	Selective activity of the histone deacetylase inhibitor AR-42 against leukemia stem cells: a novel potential strategy in acute myelogenous leukemia. *Molecular Cancer Therapeutics*, **2014**, 13, 1979-90	6.1	45
48	Interleukin 2 Receptor-α (CD25) Expression Is Associated with Shortened Overall Survival and Resistance to Induction Therapy with Plerixafor and Decitabine in Older Patients with Newly Diagnosed Acute Myeloid Leukemia (AML). *Blood*, **2014**, 124, 1041-1041	2.2	2
47	In Vivo Treatment with TG-02 Results in Increased Mobilization and Sensitization of Leukemia Stem Cells to Chemotherapeutic Agents. *Blood*, **2014**, 124, 3765-3765	2.2	
46	Selective Inhibition of the Leukemia Fusion Protein CBFβ-SMMHC By Small Molecule AI-10-49 in the Treatment of Inv(16) AML. *Blood*, **2014**, 124, 390-390	2.2	
45	Ultra-Deep Sequencing Defines Stem Cell-Specific Diversity Patterns in Acute Myelogenous Leukemia. *Blood*, **2014**, 124, 4790-4790	2.2	
44	Proteasome Inhibitor Treatment in Multiple Myeloma Can Mobilize Hematopoietic Stem Cells in the Absence of G-CSF. *Blood*, **2014**, 124, 2452-2452	2.2	
43	The Significance of GADD45A Promoter DNA Hypermethylation in AML: Association with IDH1/2 and TET2 Mutation. *Blood*, **2014**, 124, 69-69	2.2	
42	Chemical Genomic Approaches to Eradicate Leukemia Stem Cells. *Stem Cells and Cancer Stem Cells*, **2014**, 93-101		
41	Acute myelogenous leukemia stem cells: from Bench to Bedside. *Cancer Letters*, **2013**, 338, 4-9	9.9	37
40	Is minimal residual disease monitoring clinically relevant in adults with acute myelogenous leukemia?. *Current Hematologic Malignancy Reports*, **2013**, 8, 109-15	4.4	8
39	Single-Cell Mass Cytometry Reveals Phenotypic and Functional Heterogeneity In Acute Myeloid Leukemia At Diagnosis and In Remission. *Blood*, **2013**, 122, 1311-1311	2.2	2
38	Leukemia Stem/Progenitor Cells From AML Patients Treated With The Multi-Kinase Inhibitor TG02 Demonstrate Increased Proliferation and Are Sensitized To Chemotherapeutic Agents. *Blood*, **2013**, 122, 3892-3892	2.2	2
37	A-Type Proanthocyanidins Prevent Engraftment Of Primary Acute Myelogenous Leukemia Cells In Mice and Exhibit Potentially Novel Anti-Leukemia Mechanisms. *Blood*, **2013**, 122, 3962-3962	2.2	

36	Cytokine Induced Nuclear Localization Of Pyruvate Kinase M2 In Acute Myeloid Leukemia. *Blood*, **2013**, 122, 5406-5406	2.2	
35	Evolution Of Acute Myelogenous Leukemia Stem Cell Properties Following Treatment and Progression. *Blood*, **2013**, 122, 883-883	2.2	1
34	Novel Multistage Nanoparticle Drug Delivery to Ablate Leukemia Stem Cells in Their Niche.. *Blood*, **2012**, 120, 2631-2631	2.2	2
33	A-Type Proanthocyanidins From Cranberries Target Acute Myelogenous Leukemia Stem Cells.. *Blood*, **2012**, 120, 2986-2986	2.2	
32	HSP70 Inhibitor, YK5, Synergizes with Chemotherapeutic Agents and Prevents Chemoresistance in Acute Myelogenous Leukemia (AML).. *Blood*, **2012**, 120, 2476-2476	2.2	
31	Synthesis of purine-scaffold fluorescent probes for heat shock protein 90 with use in flow cytometry and fluorescence microscopy. *Bioorganic and Medicinal Chemistry Letters*, **2011**, 21, 5347-52	2.9	18
30	Affinity-based proteomics reveal cancer-specific networks coordinated by Hsp90. *Nature Chemical Biology*, **2011**, 7, 818-26	11.7	208
29	The Acrylonitrile Analog, VJ-289 Ablates Acute Myelogenous Leukemia Blast, Progenitor and Stem Cell Populations by Inducing Tubulin Acetylation and Caspase Activation. *Blood*, **2011**, 118, 2496-2496	2.2	
28	Troglitazone and Prochloroperazine Repositioned As An Anti-Leukemia Stem Cell Drug Combination Using Chemical Genomics-Based Prediction. *Blood*, **2011**, 118, 1885-1885	2.2	0
27	FLT3-ITD+ AML Blast, Progenitor and Stem Cell Populations Demonstrate Higher Sensitivity to the Hsp90 Inhibitor PU-H71,. *Blood*, **2011**, 118, 3500-3500	2.2	
26	HSP70 Inhibitor, YK5, Ablates Blast, Progenitor and Stem Cell Populations in Primary Acute Myelogenous Leukemia Cells. *Blood*, **2011**, 118, 2493-2493	2.2	
25	Investigational NEDD8-Activating Enzyme (NAE) Inhibitor, MLN4924, Demonstrates Activity Against Primary AML Blast, Progenitor and Stem Cell Populations. *Blood*, **2011**, 118, 1414-1414	2.2	1
24	High Throughput Screening Reveals Unique Sensitivity of CD34+CD38- AML Cells to Isotretinoin and Tretinoin. *Blood*, **2011**, 118, 1430-1430	2.2	
23	Dysregulated Expression of HSP70 Isoforms in Acute Myelogenous Leukemia (AML). *Blood*, **2011**, 118, 1370-1370	2.2	
22	Chemical genomic screening reveals synergism between parthenolide and inhibitors of the PI-3 kinase and mTOR pathways. *Blood*, **2010**, 116, 5983-90	2.2	66
21	Intrinsic Requirement of MicroRNA In Hox-Based Leukemia Initiating Cell Maintenance. *Blood*, **2010**, 116, 4192-4192	2.2	1
20	Lessons learned from the study of JunB: new insights for normal and leukemia stem cell biology. *Cancer Cell*, **2009**, 15, 252-4	24.3	8
19	Acute myeloid leukemia stem cells: seek and destroy. *Expert Review of Hematology*, **2009**, 2, 663-72	2.8	45

18	Identification of the Histone Deacetylase Inhibitor (HDACi), AR-42, as a Novel Anti-Leukemia Stem Cell Agent in Acute Myeloid Leukemia (AML).. *Blood*, **2009**, 114, 2070-2070	2.2	1
17	Analysis of the Anti-Leukemia Mechanism of Parthenolide.. *Blood*, **2009**, 114, 2734-2734	2.2	1
16	Chemical Genomic Screening Reveals That PI3K/mTOR Inhibition Enhances Activity of the Anti-Leukemia Stem Cell Compound Parthenolide.. *Blood*, **2009**, 114, 388-388	2.2	1
15	Modulation of Cell Surface Protein Free Thiols; A Potential Novel Mechanism of Action of the Sesquiterpene Lactone Parthenolide in Non-Hodgkin's Lymphoma.. *Blood*, **2009**, 114, 3774-3774	2.2	0
14	Chemical Derivatives of the Anti-Leukemia Stem Cell Compound 4-Benzyl-2-Methyl-1,2,4-Thiadiazolidine-3,5-Dione (TDZD-8) with Improved Activity.. *Blood*, **2009**, 114, 3764-3764	2.2	0
13	Epigenetic Signaling Is Required for HoxA9-Based Leukemic Transformation.. *Blood*, **2009**, 114, 3966-3966	2.2	
12	Discovery of agents that eradicate leukemia stem cells using an in silico screen of public gene expression data. *Blood*, **2008**, 111, 5654-62	2.2	157
11	Genes Dysregulated in a Murine Model of Leukemogenesis Comprise a Signature for Identification of Therapeutics in Humans.. *Blood*, **2008**, 112, 3349-3349	2.2	
10	Rapid and selective death of leukemia stem and progenitor cells induced by the compound 4-benzyl, 2-methyl, 1,2,4-thiadiazolidine, 3,5 dione (TDZD-8). *Blood*, **2007**, 110, 4436-44	2.2	94
9	An orally bioavailable parthenolide analog selectively eradicates acute myelogenous leukemia stem and progenitor cells. *Blood*, **2007**, 110, 4427-35	2.2	319
8	Molecular Signature for Parthenolide-Induced Apoptosis in AML CD34+ Cells Reveals Targets for Improving Induction of Leukemia-Specific Cell Death.. *Blood*, **2006**, 108, 2592-2592	2.2	1
7	The sesquiterpene lactone parthenolide induces apoptosis of human acute myelogenous leukemia stem and progenitor cells. *Blood*, **2005**, 105, 4163-9	2.2	544
6	The PKCβ Selective Inhibitor, Enzastaurin (LY317615), Inhibits Growth of Human Lymphoma Cells.. *Blood*, **2005**, 106, 1483-1483	2.2	9
5	Considerations for targeting malignant stem cells in leukemia. *Cancer Control*, **2004**, 11, 97-104	2.2	68
4	Osteoblastic Cells and the Hematopoietic Microenvironment: The Notch ligand Jagged1 Is Increased in Osteoblastic Stromal Cells by Parathyroid Hormone (PTH)Treatment.. *Blood*, **2004**, 104, 1284-1284	2.2	
3	Preferential induction of apoptosis for primary human leukemic stem cells. *Proceedings of the National Academy of Sciences of the United States of America*, **2002**, 99, 16220-5	11.5	368
2	Expression of tumor-suppressor genes interferon regulatory factor 1 and death-associated protein kinase in primitive acute myelogenous leukemia cells. *Blood*, **2001**, 97, 2177-9	2.2	47
1	Nuclear factor-kappaB is constitutively activated in primitive human acute myelogenous leukemia cells. *Blood*, **2001**, 98, 2301-7	2.2	631